Altimmune (ALT) Cash & Equivalents (2010 - 2026)

Altimmune (ALT) has 17 years of Cash & Equivalents data on file, last reported at $97.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 98.68% year-over-year to $97.6 million in Q1 2026; TTM through Mar 2026 was $97.6 million, a 98.68% increase from a year earlier, with the FY2025 full-year figure at $43.8 million, up 18.49% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $97.6 million, up from $43.8 million in the prior quarter.
• Over the last five years, Cash & Equivalents for ALT reached as high as $183.1 million in Q2 2025 and fell as low as $31.5 million in Q3 2024.
• Historically, Cash & Equivalents has averaged $95.5 million across 5 years, with a median of $97.6 million in 2026.
• Across the five-year window, Cash & Equivalents slumped 72.65% in 2024 and soared 220.36% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $111.1 million in 2022, then grew by 21.62% to $135.2 million in 2023, then slumped by 72.65% to $37.0 million in 2024, then rose by 18.49% to $43.8 million in 2025, then soared by 122.92% to $97.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $97.6 million in Q1 2026, $43.8 million in Q4 2025, and $61.2 million in Q3 2025.